The FDA designates Johnson & Johnson’s
cadazolid an Orphan Drug for the treatment of
Clostridium difficile (C. diff) infection
in pediatric patients.
Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
Cadazolid is a quinoxolidinone antibiotic being developed by Actelion.
Aug. 9, 2017 7:40 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Editor